Reimbursement of biosimilars in Poland: is there a link to health technology assessment? - Wikidata - wikimedia - TriplyDB

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

http://www.wikidata.org/entity/Q53317811

about

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

http://www.wikidata.org/entity/Q53317811

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@en

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@nl

type

label

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@en

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@nl

prefLabel

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@en

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@nl

P1433

Q53317811-1FE9441B-6115-4EB4-B460-CD0D4952FA6B

P1476

Q53317811-0C6CA63C-9478-47B2-8684-77C3456A15B1

P2093

Q53317811-878349EC-98A4-49CC-B9BA-6E194198A5A8

P2860

Q53317811-5380F037-D84D-4EA3-BED2-C9826630029B

Q53317811-64349AF5-23FC-40E9-94C8-1989B6877CC5

Q53317811-6B6D7ABF-1914-4709-9DAF-7CF9DFF04492

Q53317811-80D16619-2434-45A5-97A6-64BF5FC10B02

P304

Q53317811-34D2E7F4-033F-4689-A737-28387E54A489

P31

Q53317811-ABDFA9B2-792E-42DF-90E0-6C53637A1F53

P356

Q53317811-2F359F72-8632-4EBB-8FDF-0C7D1EAD0014

P433

Q53317811-83F7FA97-EBB9-45F5-9FA4-6CB1E44BA5D7

P478

Q53317811-7216C314-DC83-41D6-BFB8-04333D1F2799

P50

Q53317811-44A51ADB-7C09-4BFB-A973-E03C41C7337C

P577

Q53317811-76A0DC0F-04E6-4418-86B2-9E54F4733572

P698

Q53317811-455A9273-9205-45E2-96E8-B83A40FC4829

P356

14737167.2016.1141051

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Reimbursement of biosimilars in Poland: is there a link to health technology assessment?

@en

P2093

Dominika Neumann

http://www.w3.org/2001/XMLSchema#string

P2860

Biosimilar medicines and cost-effectiveness.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Biosimilar safety factors in clinical practice.

P304

781-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737167.2016.1141051

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26768654

http://www.w3.org/2001/XMLSchema#string